| Entry |
|
|---|
| Name |
Rituximab (USAN/INN);
Rituximab (genetical recombination) (JAN);
Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN);
Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN);
Rituximab-abbs;
Rituximab-pvvr;
Rituxan (TN);
Truximab (TN)
|
|---|
| Product |
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (mixture): | D11393<US> |
|
|---|
| Efficacy |
Antineoplastic, Anti-CD20 antibody |
|---|
| Disease |
Non-Hodgkin's lymphoma (CD20-positive) [DS: H02418] Chronic lymphocytic leukemia (CD20-positive) [DS: H00005] Rheumatoid arthritis [DS: H00630] Granulomatosis with polyangiitis; Wegener's granulomatosis [DS: H01655] Microscopic polyangiitis [DS: H01658] Pemphigus vulgaris [DS: H01648] |
|---|
| Comment |
Monoclonal antibody
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC02 Rituximab
D02994 Rituximab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Rituximab
D02994 Rituximab (USAN/INN)
Immunological Agents
Immunosuppressants
Immunosupressants, Other
Rituximab
D02994 Rituximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D02994 Rituximab (USAN/INN); Rituximab (genetical recombination) (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD20
D02994 Rituximab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02994
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02994
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02994
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D02994
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
